

September 1, 2020


Announcements
Didactic: What's new in flu
Cases & Questions




September 17th, 2019


#### Didactic


What's New in Influenza






InfluenzaA drifting + Shifting Influenza B Only drifling












# CDC estimates\* that, from **October 1, 2019**, through **April 4, 2020**, there have been:





410,000 – 740,000 flu hospitalizations



NOTE: The week of April 4 was the last week in-season influenza burden estimates will be provided for the 2019-2020 season.

Figure 2: Influenza Positive Tests Reported to CDC, WA Commercial Laboratories








Figure 2: Influenza Positive Tests Reported to CDC, WA Commercial Laboratories








#### Influenza Virus Identification




Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2019-2020 and Selected Previous Seasons






Pneumonia and Influenza Mortality from the National Center for Health Statistics Mortality Surveillance System Data through the week ending August 22, 2020, as of August 27, 2020







The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source:

Global Influenza Surveillance and Response System (GISRS), FluNet (www.who.int/flunet)




@WHO 2019. All rights reserved.



#### Percentage of respiratory specimens that tested positive for influenza By influenza transmission zone

Map generated on 14 August 2020



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.



Data source: Global Influenza Surveillance and Response System (GISRS), FluNet (www.who.int/flunet) Copyright WHO 2020. All rights reserved.



# **Testing and Treatment**

#### Testing linked to intent to treat

- Influenza PCR Panel
  - NP swab for influenza PCR testing
  - Reflexive subtyping and potential oseltamivir resistance
- Hospitalized with suspected or confirmed influenza
- Suspected or confirmed severe influenza illness, including signs of lower tract infection (pneumonia)
- Patients at high risk for influenza complications
  - ALL pregnant women (through 2 weeks postpartum)
- DO NOT test or treat patients with mild illness without risk factors for influenza complications




## Medications for Flu 1

#### **Adamantanes**

- Amantadine
- Ramantadine
- Neuraminadase inhibitors
  - Oseltamavir
  - Zanamavir
  - Peramavir
- Endonuclease Inhibitor
  - Baloxavir







#### the benefits of flu vaccination 2017-2018

The estimated number of flu illnesses prevented by vaccination during the 2017-2018 season:

7 million

About the population of New York City



The estimated number of flu hospitalizations prevented by vaccination during the 2017-2018 season:

109,000


About the number of vehicles crossing the Golden Gate Bridge each day



The estimated number of flu deaths prevented by vaccination during the 2017-2018 season:

8,000

Twice the number of hospitals in the United States



DATA: Journal Clinical Infectious Disease, Effects of Influenza Vaccination in the United States during the 2017–2018 Influenza Season, https://doi.org/10.1093/cid/ciz075



get vaccinated www.cdc.gov/flu

#### Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season

Recommendations and Reports / August 21, 2020 / 69(8);1-24

Lisa A. Grohskopf, MD<sup>1</sup>; Elif Alyanak, MPH<sup>1,2</sup>; Karen R. Broder, MD<sup>3</sup>; Lenee H. Blanton, MPH<sup>1</sup>; Alicia M. Fry, MD<sup>1</sup>; Daniel B. Jernigan, MD<sup>1</sup>; Robert L. Atmar, MD<sup>4</sup> (<u>View author affiliations</u>)


- A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus (updated)
- A/Hong Kong/2671/2019 (H3N2)-like virus (updated)
- B/Washington/02/2019 (B/Victoria lineage)-like virus (updated)

For quadrivalent vaccines +

plus B/Phuket/3073/2013-like (Yamagata lineage) virus.




Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season





Trade name (Manufacturer)	Presentation	Age indication	HA (IIVs and RIV4) or virus count (LAIV4) for each vaccine virus (per dose)	Route	Mercury (from thimerosal) µg/0.5 mL
IIV4					
Standard dose, egg based <sup>†</sup> Afluria Quadrivalent (Seqirus)	0.25-mL PFS <sup>§</sup> 0.5-mL PFS 5.0-mL MDV <sup>§</sup>	6 through 35 mos ≥3 yrs ≥6 mos (needle/syringe) 18 through 64 yrs (jet injector)	7.5 μg/0.25 mL 15 μg/0.5 mL	IM¶	  24.5
Fluarix Quadrivalent (GlaxoSmithKline) FluLaval Quadrivalent (GlaxoSmithKline) Fluzone Quadrivalent (Sanofi Pasteur)	0.5-mL PFS 0.5-mL PFS 0.5-mL PFS** 0.5-mL SDV 5.0-mL MDV	≥6 mos ≥6 mos ≥6 mos ≥6 mos ≥6 mos	15 $\mu$ g/0.5 mL 15 $\mu$ g/0.5 mL 15 $\mu$ g/0.5 mL	IM <sup>¶</sup> IM <sup>¶</sup>	    25
Standard dose, cell culture based (ccIIV4) Flucelvax Quadrivalent (Seqirus)	0.5-mL PFS 5.0-mL MDV	≥4 yrs ≥4 yrs	15 μg/0.5 mL	IM¶	 25
High dose, egg based <sup>†</sup> (HD-IIV4) Fluzone High-Dose Quadrivalent (Sanofi Pasteur)	0.7-mL PFS	≥65 yrs	60 μg/0.7 mL	IM¶	_
Standard dose, egg based <sup>†</sup> with MF59 adjuvant (allV4) Fluad Quadrivalent (Seqirus)	0.5-mL PFS	≥65 yrs	15 μg/0.5 mL	ΙΜ <sup>¶</sup>	_
IIV3 Standard dose, egg based <sup>†</sup> with MF59 adjuvant (aIIV3) Fluad (Seqirus) RIV4	0.5-mL PFS	≥65 yrs	15 μg/0.5 mL	IM¶	_
Recombinant HA Flublok Quadrivalent (Sanofi Pasteur)	0.5-mL PFS	≥18 yrs	45 μg/0.5 mL	IM <sup>¶</sup>	_
LAIV4 Egg based <sup>†</sup> FluMist Quadrivalent (AstraZeneca)	0.2-mL prefilled single-use intranasal sprayer	2 through 49 yrs	10 <sup>6.5-7.5</sup> fluorescent focus units/0.2 mL	NAS	-
					<b>#</b>

# Egg Allergy





### Flu and COVID-19

#### MANY UNKNOWNS this year

- Will COVID and Flu be co-circulating in the community?
  - Likely YES
- Can one person get co-infected with both?
  - Likely YES
  - Does it matter? Maybe



# **Audience Questions**

Will your hospital mandate influenza vaccination for HCWs this season?

- 1) Yes
- 2) No
- 3) Don't know



# **Audience Questions**

How will your hospital manage the ongoing need for COVID testing & case investigation and influenza vaccination campaign? Isn't all the same people!?



# Discussion, questions, comments?



